At the news
? NEUTRALIMPACT 5/10 8-K filed May 13, 2026 at 08:32 ET
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in Q1 2025, and revenue of $1.3M from its Ono collaboration. The key catalysts are regulatory and clinical: FT819 was selected for the FDA's CDRP program, the Phase 2 RECLAIM-LN trial is on track for H2 2026, and the operating runway was extended into 2028 with $174.8M in cash. However, the company remains a pre-revenue clinical-stage biotech with no approved products and a net loss of $31.2M for the quarter.
- Cash, cash equivalents, and investments of $174.8M as of March 31, 2026, providing runway into 2028
- Net loss of $31.2M for Q1 2026, improved from $37.6M loss in Q1 2025
- Revenue of $1.3M from Ono Pharmaceutical collaboration, down from $1.6M in Q1 2025
- FT819 selected for FDA's CDRP program, potentially accelerating regulatory pathway
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access